Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine. (25th September 2020)

• Record Type: Journal Article
• Authors: Pintado, Claire; Delaugerre, Constance; Molina, Jean-Michel
• Is Part Of: Open forum infectious diseases. Volume 7:Number 9(2020)
• Publication Date: 2020-09-25
• Subjects: Acute hepatitis B -- Long-acting antiretroviral HIV -- cabotegravir -- rilpivirine -- HBV vaccination; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa367
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Maintenance antiretroviral therapy with combination of two injectable long-acting drugs, cabotegravir and rilpivirine, is a new strategy addressing the challenges of daily adherence to oral pills that has shown non-inferior efficacy to standard of care therapy in patients with suppressed HIV-infection. Patients co-infected with hepatitis B virus (HBV) are not eligible for this dual therapy since it has no activity against HBV, but this strategy should also be restricted to patients with anti-HBs antibodies since people with HIV are still at risk of HBV acquisition due to high risk behavior and since HBV vaccination does not always elicit anti-HBs antibodies, as highlighted in the case report below.